PROGNOSTIC CALCULATORS OF SURVIVAL
FOR PATIENT WITH RECURRENT GBM

Cited in

New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials.  Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, Campone MM, Twelves CC, Raymond E, Hegi ME, Lacombe D, van den Bent MJ. Eur J Cancer. 2012 May;48(8):1176-848

By using theses calculators you agree with the following License and Disclaimer

These models were developed for patients who were previously treated by chemoradiation with temozolomide according to the results of Stupp at al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. N Engl J Med. 2005 Mar 10;352(10):987-96.

Calculators for PFS and OS
Corticosteroids Median PFS (months)
(95% Confidence Interval)
-
WHO Performance status PFS6 months (%)
(95% Confidence Interval)
-
Number of target lesions Median OS (months)
(95% Confidence Interval)
-
Maximum diameter of the largest target lesion OS12 months (%)
(95% Confidence Interval)
-

Examples:

A patient with a performance status greater than 0 and more than one target lesion is predicted to have a median PFS of 1.6 months (1.4-1.8) and poor chance to be alive and free of progression at 6 months (PFS6= 2.2 % (0.2-10.2)). Patients with good performance status (PS=0) and one target lesion have an estimated median PFS of 3.3 months (1.9-5.5) months and PFS6 of 32.7% (19.3-44.8) . For overall survival, patients predicted with a good prognosis have performance status 0, no baseline steroids, one target lesion and largest lesion has a maximum diameter equal to or lower than 42 mm. Their median OS is 18.2 month (11.4-38.9) months and OS12is 60.6% (46.0-72.3). . Patients with poor performance status (PS2), steroids administered, more than one target lesion, and a maximum diameter of the largest lesion greater than 42 mm are predicted with a median OS of 2.6 months (1.9-3.9) and OS12 equal to 0% (0-0.3).

Kaplan Meier progression free and overall survival estimates for the main prognostic factors Calibration of the prognostic models

Calibration of the pronostic models